LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.36 -5.56

Buy Sell

Overview

Share price change

24h

Current

Min

1.34

Max

1.45

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+179.56% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.2M 173M
Previous open	6.92
Previous close	1.36

News Sentiment

By Acuity

20%

80%

37 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 mar 2026, 23:39 UTC

Hot Stocks

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar 2026, 23:20 UTC

Earnings

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar 2026, 21:43 UTC

Earnings

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar 2026, 22:30 UTC

Earnings

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar 2026, 22:13 UTC

Earnings

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Rev $66.8M >LAC

4 mar 2026, 21:53 UTC

Earnings

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar 2026, 21:52 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:50 UTC

Earnings

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q Rev $165.2M >BULL

4 mar 2026, 21:48 UTC

Earnings

Webull 4Q EPS 1c >BULL

4 mar 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 mar 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar 2026, 21:40 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:36 UTC

Major News Events

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar 2026, 21:27 UTC

Earnings

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar 2026, 21:16 UTC

Earnings

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q EPS $1.50 >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Net $7.35B >AVGO

4 mar 2026, 21:15 UTC

Earnings

Broadcom 1Q Rev $19.31B >AVGO

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

179.56% upside

12 Months Forecast

Average 3.83 USD 179.56%

High 7 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

37 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.